Detecting HERV-K ENV and neutralizing induced neurotoxicity in sporadic ALS: a rationale for precision medicine
New data supporting a new precision medicine approach for ALS patients with GeNeuro’s GNK-301 presented at the 35th International Symposium on ALS/MND
Geneva, Switzerland, December 6, 2024 – 6:30 pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as amyotrophic lateral sclerosis (ALS), today announced that groundbreaking findings on a potential precision medicine strategy for ALS with GeNeuro’s GNK-301 were […]
New data presented at the ECTRIMS 2024 Congress in Copenhagen shows that Temelimab rescues the neurodegenerative effects of HERV-W in an MS model
Geneva, Switzerland, September 19, 2024 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that new findings on the anti-neurodegenerative effect of Temelimab in an MS model were presented as […]
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
MS Journal, July 9, 2021 https://geneuro.ch/data/news/MSJ-July-21-Efficacy-and-safety-of-temelimab-in-multiple-sclerosis.pdf
Temelimab for prevention of neurodegeneration: preclinical safety profile and design of the ProTEct-MS (temelimab following rituximab in RMS) study
MS Virtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13 https://geneuro.ch/data/news/P0239-Piehl.pdf
pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis
PNAS, July 23, 2019 https://www.pnas.org/content/116/30/15216
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env
Clinical Therapeutics, July 13, 2019 https://www.clinicaltherapeutics.com/article/S0149-2918(19)30296-6/pdf
ECTRIMS 2109 – Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks
Phase IIb safety and efficacy data on temelimab at week 96 from the ANGEL-MS study https://geneuro.ch/data/news/P1379-Ectrims-2019.pdf
Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses
Frontiers in Genetics, July 11, 2019 https://www.frontiersin.org/articles/10.3389/fgene.2019.00655/full
Variation in proviral content among human genomes mediated by LTR recombination
Mobile DNA, December 18, 2018 https://geneuro.ch/data/news/2018-12-Mobile-DNA-Variation-in-proviral-content-among-human-genomes-mediated-by-LTR-recombination-Thomas-Perron-Feschotte.pdf